HomeCompareICPT vs KO

ICPT vs KO: Dividend Comparison 2026

ICPT yields 10.53% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICPT wins by $6.0K in total portfolio value
10 years
ICPT
ICPT
● Live price
10.53%
Share price
$19.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.1K
Annual income
$2,037.15
Full ICPT calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — ICPT vs KO

📍 ICPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPTKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPT + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICPT pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPT
Annual income on $10K today (after 15% tax)
$894.74/yr
After 10yr DRIP, annual income (after tax)
$1,731.58/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, KO beats the other by $1,926.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPT + KO for your $10,000?

ICPT: 50%KO: 50%
100% KO50/50100% ICPT
Portfolio after 10yr
$37.1K
Annual income
$3,170.46/yr
Blended yield
8.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

ICPT
Analyst Ratings
16
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$22.11
+16.4% upside vs current
Range: $10.00 — $44.00
Altman Z
-5.0
Piotroski
3/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPT buys
0
KO buys
0
No recent congressional trades found for ICPT or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPTKO
Forward yield10.53%2.70%
Annual dividend / share$2.00$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$40.1K$34.1K
Annual income after 10y$2,037.15$4,303.79
Total dividends collected$15.4K$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$22.11$84.88

Year-by-year: ICPT vs KO ($10,000, DRIP)

YearICPT PortfolioICPT Income/yrKO PortfolioKO Income/yrGap
1← crossover$11,753$1,052.63$10,846$335.73+$907.00ICPT
2$13,732$1,156.19$11,829$430.64+$1.9KICPT
3$15,955$1,262.49$12,988$555.50+$3.0KICPT
4$18,443$1,370.97$14,372$721.34+$4.1KICPT
5$21,215$1,481.06$16,049$944.01+$5.2KICPT
6$24,292$1,592.22$18,114$1,246.74+$6.2KICPT
7$27,697$1,703.90$20,702$1,664.24+$7.0KICPT
8$31,451$1,815.59$24,008$2,249.48+$7.4KICPT
9$35,580$1,926.82$28,317$3,085.19+$7.3KICPT
10$40,107$2,037.15$34,065$4,303.79+$6.0KICPT

ICPT vs KO: Complete Analysis 2026

ICPTStock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Full ICPT Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this ICPT vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPT vs SCHDICPT vs JEPIICPT vs OICPT vs MAINICPT vs PEPICPT vs PGICPT vs JNJICPT vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.